Lidokain Aguettant

Lidocaine Hydrochloride Monohydrate, the active ingredient in Lidokain Aguettant, is a local anesthetic presented as a sterile solution for epidural, infiltration, intravenous and subcutaneous use. It provides reversible nerve impulse blockade to produce local anesthesia for minor surgical procedures, epidural analgesia, and regional anesthesia in adult patients.

GNH USA supplies Lidokain Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets and providing reliable logistics for timely delivery.

Lidokain Aguettant, containing lidocaine, is employed for local anesthesia across several procedural pathways.

- Minor surgical procedures: provides pain‑free anesthesia for skin, mucosal or superficial surgeries. - Epidural analgesia: delivers analgesic effect for labor, postoperative pain or chronic pain management. - Regional (infiltration or intravenous) anesthesia: enables nerve block for limb surgeries or intravenous regional anesthesia (Bier block).

Lidokain Aguettant may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Transient burning or tingling at the injection site - Mild hypotension - Nausea - Dizziness

Serious or Rare Side Effects: - Anaphylactic reaction (severe allergy) - Cardiac arrhythmias, including ventricular tachycardia - Central nervous system toxicity such as seizures or loss of consciousness - Methemoglobinemia, a disorder affecting oxygen transport

When using Lidokain Aguettant, several safety considerations should be observed.

- Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid in patients with severe heart block or conduction disorders. - Dose limits: adhere to recommended maximum doses to prevent systemic toxicity. - Concurrent CNS depressants: use caution when combined with other agents that lower seizure threshold. - Pregnancy and lactation: use only if the benefit outweighs the potential risk and after consulting an obstetric specialist. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidokain Aguettant can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma levels and toxicity. - CYP1A2 inhibitors (e.g., fluvoxamine): can raise lidocaine concentrations. - Beta‑blockers (e.g., propranolol): may potentiate cardiac effects of lidocaine.

Moderate Interactions (Monitor Closely): - Other local anesthetics: additive risk of systemic toxicity. - General anesthetics (e.g., propofol): may enhance central nervous system depression. - Diuretics (e.g., furosemide): may alter plasma protein binding and affect lidocaine levels.